Tag
Earlier initiation of biologic therapies in severe asthma improves clinical remission rates, reduces exacerbations, preserves lung function, and decreases corticosteroid dependence, supporting a shift from reserving to preserving treatment
The 2/20/20 risk stratification model identifies a smaller, truly high-risk SMM group with higher progression rates than the AQUILA trial criteria, suggesting better targeting for early intervention.
The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in
A secondary analysis of a randomized clinical trial reveals that parent-led enhanced developmental intervention, beginning in the NICU and spanning two years, significantly improves executive function domains—including attention, inhibition
The LOVE‑CD phase 4 cohort shows vedolizumab yields higher sustained clinical and endoscopic remission and fewer serious adverse events when given early in Crohn’s disease versus later-stage, previously biologic‑exposed disease.
Early secukinumab use in newly diagnosed psoriatic arthritis delivers faster clinical improvement at 3 months compared to standard care, but this advantage diminishes by 6 months and beyond.
